assisTek, the Leader in Innovative Electronic Patient-Reported Outcomes (ePRO) Solutions and Patient Questionnaires for Clinical Trials, announced that it has been awarded a contract to use their state-of-the-art smart phone technology to collect data from patients at home on electronic diaries in an upcoming large multinational clinical trial.
The smart phone chosen for the trial will be an HTC Fuze, which looks similar to the Apple iPhone. It provides significant advantages over past electronic diary solutions based on Palm technology.
Palm-based devices require patients to install, implement, and use a modem interface in their home on a daily basis to transfer the data from the device to a central data repository. Because patients participating in clinical trials often have significant other challenges, this requirement can be difficult and time-consuming for all clinical trial participants -- the patients, clinicians, and technology vendors.
* assisTek’s smart phone product, the MobilePRO, eliminates much of the work and hassle associated with Palm devices.
* The smart phone transfers data automatically through cell phone networks using the SIM card inside the phone.
* This technological breakthrough will save countless hours of work in clinical trial data collection.
“We are very proud to lead the industry in providing innovative electronic diary solutions to collect data from patients in clinical trials,” said Joy Hebert, Chief Executive Officer of assisTek. “We introduced the collection of patient-reported outcomes on Apple iPhones and internet platforms last year, and are proud to now deliver this new breakthrough product this year.”
Not only does this technology significantly reduce the work and hassle factor in collecting data from patients, it is also a beautiful product. It includes striking colors and photos not available in the older technologies offered by other vendors.
“We look forward to providing our clinical trial participants with this capability. Participating in a clinical trial is a significant time commitment for patients,” stated Dr. Temitayo Ajayi, Medical Director for PTC Therapeutics. “We believe it is beneficial to utilize state-of-the-art technology, such as the assisTek smart phones, to minimize the reporting burden and potentially increase compliance utilizing accessible technologies.”